Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Melatonin osteoporosis prevention study (MOPS): a randomized, double-blind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in perimenopausal women.

Kotlarczyk MP, Lassila HC, O'Neil CK, D'Amico F, Enderby LT, Witt-Enderby PA, Balk JL.

J Pineal Res. 2012 May;52(4):414-26. doi: 10.1111/j.1600-079X.2011.00956.x. Epub 2012 Jan 6.

PMID:
22220591
2.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
3.

Evaluation of modal damping factor as a diagnostic tool for osteoporosis and its relation with serum osteocalcin and collagen I N-telopeptide for monitoring the efficacy of alendronate in ovariectomized rats.

Christopoulou GE, Stavropoulou A, Anastassopoulos G, Panteliou SD, Papadaki E, Karamanos NK, Panagiotopoulos E.

J Pharm Biomed Anal. 2006 Jun 7;41(3):891-7. Epub 2006 Feb 20.

PMID:
16488571
4.

Vitamin K supplementation does not significantly impact bone mineral density and biochemical markers of bone in pre- and perimenopausal women.

Volpe SL, Leung MM, Giordano H.

Nutr Res. 2008 Sep;28(9):577-82. doi: 10.1016/j.nutres.2008.06.006.

PMID:
19083462
5.
6.

Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.

Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.

J Bone Miner Res. 2005 Nov;20(11):1905-11. Epub 2005 Jul 18.

7.

Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.

Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM, Woodson G, Levine AB, Constantine G, Delmas PD.

J Bone Miner Res. 2008 Apr;23(4):525-35. Erratum in: J Bone Miner Res. 2008 Jun;23(6):972.

8.

Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial.

Soares CN, Joffe H, Rubens R, Caron J, Roth T, Cohen L.

Obstet Gynecol. 2006 Dec;108(6):1402-10.

PMID:
17138773
9.
10.

Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.

McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkänen L, Kenraali J, Aropuu S, Kanis JA.

J Bone Miner Res. 2004 May;19(5):728-36. Epub 2004 Jan 19.

11.

A randomized double-blind placebo-controlled trial of a Chinese herbal medicine preparation (Jiawei Qing'e Fang) for hot flashes and quality of life in perimenopausal women.

Xia Y, Zhao Y, Ren M, Zhang J, Wang Y, Chang Y, Fu S, Fan G, Zhu Y, Huang Y, Gao X.

Menopause. 2012 Feb;19(2):234-44. doi: 10.1097/gme.0b013e3182273177.

PMID:
22089177
12.

Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.

Choi HJ, Im JA, Kim SH.

Maturitas. 2008 Jun 20;60(2):170-6. doi: 10.1016/j.maturitas.2008.05.003. Epub 2008 Jun 24.

PMID:
18572334
13.

Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.

Ste-Marie LG, Sod E, Johnson T, Chines A.

Calcif Tissue Int. 2004 Dec;75(6):469-76. Epub 2004 Oct 14.

PMID:
15478000
14.

Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.

Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ.

J Bone Miner Res. 1999 Jul;14(7):1182-8.

16.

Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.

Välimäki MJ, Laitinen K, Patronen A, Puolijoki H, Seppänen J, Pylkkänen L, Aranko SM, Sairanen S, Blåfield H, Rekiaro M, Väisänen K, Kormano M, Mäkinen L, Salmi J, Ala-Kaila K, Perttilä J, Vesterinen K, Koivunoro K; Probone Study Group.

Osteoporos Int. 2002 Dec;13(12):937-47.

PMID:
12459936
18.
19.

Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women.

Tseng LN, Sheu WH, Ho ES, Lan HH, Hu CC, Kao CH.

Metabolism. 2006 Jun;55(6):741-7.

PMID:
16713432
20.

Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women.

Rejnmark L, Buus NH, Vestergaard P, Heickendorff L, Andreasen F, Larsen ML, Mosekilde L.

J Bone Miner Res. 2004 May;19(5):737-44. Epub 2004 Feb 16.

Supplemental Content

Support Center